Compounds > alpha-aminopyridine
Page last updated: 2024-08-21

alpha-aminopyridine and Hyperlipoproteinemia Type I

alpha-aminopyridine has been researched along with Hyperlipoproteinemia Type I in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, J; Lin, T; Majumdar, T; Meyers, D; Mita, S; Pal, P; Rebello, S; Sunkara, G1
Chen, J; Golla, G; Hirano, M; Lin, T; Majumdar, T; Meyers, D; Pal, P; Pinot, P; Rebello, S; Sunkara, G1
Amer, A; Chen, J; Gaudet, D; Jiang, L; Meyers, CD; Tremblay, K1
Chen, J; Crissey, A; Kulmatycki, K; Majumdar, T; Meyers, CD; Movva, A; Neelakantham, S; Noe, A; Salunke, A1

Trials

4 trial(s) available for alpha-aminopyridine and Hyperlipoproteinemia Type I

ArticleYear
Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor.
    Clinical pharmacokinetics, 2015, Volume: 54, Issue:7

    Topics: Acetates; Aged; Aminopyridines; Body Mass Index; Case-Control Studies; Diacylglycerol O-Acyltransferase; Enzyme Inhibitors; Female; Humans; Hyperlipoproteinemia Type I; Male; Middle Aged; Protein Binding; Renal Insufficiency

2015
Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor.
    Clinical pharmacokinetics, 2015, Volume: 54, Issue:7

    Topics: Acetates; Aminopyridines; Body Mass Index; Diacylglycerol O-Acyltransferase; Enzyme Inhibitors; Female; Glucuronides; Hepatic Insufficiency; Humans; Hyperlipoproteinemia Type I; Male; Middle Aged; Protein Binding

2015
Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome.
    Lipids in health and disease, 2015, Feb-18, Volume: 14

    Topics: Acetates; Adult; Aged; Aminopyridines; Apolipoprotein B-48; Diacylglycerol O-Acyltransferase; Female; Humans; Hyperlipoproteinemia Type I; Male; Middle Aged; Triglycerides

2015
Effect of Pradigastat, a Diacylglycerol Acyltransferase 1 Inhibitor, on the QTcF Interval in Humans.
    Clinical pharmacology in drug development, 2016, Volume: 5, Issue:6

    Topics: Acetates; Adolescent; Adult; Aminopyridines; Body Mass Index; Diacylglycerol O-Acyltransferase; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Enzyme Inhibitors; Fluoroquinolones; Healthy Volunteers; Heart Rate; Humans; Hyperlipoproteinemia Type I; Long QT Syndrome; Male; Moxifloxacin; Young Adult

2016